Silencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNA.

Journal

ACS pharmacology & translational science
ISSN: 2575-9108
Titre abrégé: ACS Pharmacol Transl Sci
Pays: United States
ID NLM: 101721411

Informations de publication

Date de publication:
09 Apr 2021
Historique:
received: 09 10 2020
entrez: 16 4 2021
pubmed: 17 4 2021
medline: 17 4 2021
Statut: epublish

Résumé

Oncogenic mutations in the

Identifiants

DOI: 10.1021/acsptsci.0c00165 PMID: 33860195 PMC: PMC8033609
pubmed: 33860195
doi: 10.1021/acsptsci.0c00165
pmc: PMC8033609
doi:

Types de publication

Journal Article

Langues

eng

Pagination

703-712

Subventions

Organisme : NCI NIH HHS
ID : R21 CA179193
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA042978
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA175747
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA199235
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA196510
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA215075
Pays : United States
Organisme : NCI NIH HHS
ID : R41 CA246848
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA203657
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA232113
Pays : United States

Informations de copyright

© 2021 American Chemical Society.

Déclaration de conflit d'intérêts

The authors declare the following competing financial interest(s): S.H.A., A.D.C., C.J.D., and C.V.P. hold intellectual property interests and/or an issued U.S. patent on this work. C.V.P. is the founder of EnFuego Therapeutics, Inc. and holds equity in the company. S.H.A. and H.H. are employees of EnFuego Therapeutics. C.J.D. is an advisory board member for Anchiano Therapeutics, Deciphera Pharmaceuticals, and Mirati Therapeutics. C.J.D. has received research funding support from Deciphera Pharmaceuticals, Mirati Therapeutics, and SpringWorks Therapeutics. C.J.D. has consulted for Axon Advisors LLC, Eli Lilly, Jazz Therapeutics, Ribometrix, Sanofi, SVB Leerink, SmartAnalyst, Third Bridge, and Turning Point Therapeutics. A.D.C. has consulted for Eli Lilly, Mirati Therapeutics, and SpringWorks Therapeutics and has received research funding support from Mirati Therapeutics and SpringWorks Therapeutics.

Références

Nat Biotechnol. 2017 Mar;35(3):238-248
pubmed: 28244990
Cancer Cell. 2020 Jan 13;37(1):3-4
pubmed: 31951561
Nucleic Acids Res. 2005 Mar 21;33(5):1671-7
pubmed: 15781493
Nature. 2020 Jan;577(7790):421-425
pubmed: 31915379
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Nat Rev Drug Discov. 2014 Nov;13(11):828-51
pubmed: 25323927
Oncotarget. 2011 Nov;2(11):862-73
pubmed: 22113502
Nature. 1998 Feb 19;391(6669):806-11
pubmed: 9486653
Sci Transl Med. 2017 Jun 14;9(394):
pubmed: 28615361
N Engl J Med. 2018 Jul 5;379(1):11-21
pubmed: 29972753
Cold Spring Harb Perspect Med. 2018 Sep 4;8(9):
pubmed: 29229669
J Cell Sci. 2016 Apr 1;129(7):1287-92
pubmed: 26985062
Oncogene. 2003 Feb 27;22(8):1243-6
pubmed: 12606951
Leukemia. 2015 May;29(5):1032-40
pubmed: 25371176
Science. 2017 Mar 17;355(6330):1158-1163
pubmed: 28302824
Cell. 2018 Jan 25;172(3):578-589.e17
pubmed: 29373830
Cancer Discov. 2014 Oct;4(10):1182-1197
pubmed: 25100204
Mol Cancer Ther. 2014 Dec;13(12):2876-85
pubmed: 25281617
Ther Adv Med Oncol. 2015 May;7(3):170-80
pubmed: 26673580
Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):E3553-61
pubmed: 25114235
Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W124-9
pubmed: 15215364
Sci Rep. 2018 Mar 28;8(1):5319
pubmed: 29593296
N Engl J Med. 2020 Jun 11;382(24):2289-2301
pubmed: 32521132
Cell Chem Biol. 2020 Jan 16;27(1):19-31.e6
pubmed: 31883964
Int J Colorectal Dis. 2011 Oct;26(10):1241-8
pubmed: 21603900
Nature. 2019 Nov;575(7781):217-223
pubmed: 31666701
Exp Ther Med. 2019 Dec;18(6):5061-5071
pubmed: 31798726
Acc Chem Res. 2019 Apr 16;52(4):1036-1047
pubmed: 30912917
Cancer Discov. 2020 Jan;10(1):54-71
pubmed: 31658955
PLoS One. 2011;6(10):e25711
pubmed: 22046245
Nat Med. 2008 Dec;14(12):1351-6
pubmed: 19029981
Oncol Lett. 2013 May;5(5):1741-1743
pubmed: 23761841
Cancer Cell. 2014 Mar 17;25(3):272-81
pubmed: 24651010
Cancer Cell. 2017 Aug 14;32(2):185-203.e13
pubmed: 28810144
Nature. 2013 Nov 28;503(7477):548-51
pubmed: 24256730
Semin Cell Dev Biol. 2016 Oct;58:60-9
pubmed: 27422332

Auteurs

Bjoern Papke (B)

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

Salma H Azam (SH)

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
EnFuego Therapeutics, Inc., Nashville, Tennessee 37232, United States.

Anne Y Feng (AY)

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

Christina Gutierrez-Ford (C)

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

Hayden Huggins (H)

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
EnFuego Therapeutics, Inc., Nashville, Tennessee 37232, United States.

Pradeep S Pallan (PS)

Department of Biochemistry, Vanderbilt University, Nashville, Tennessee 37232, United States.

Amanda E D Van Swearingen (AED)

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

Martin Egli (M)

Department of Biochemistry, Vanderbilt University, Nashville, Tennessee 37232, United States.

Adrienne D Cox (AD)

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Department of Radiation Oncology, Department of Pharmacology, Department of Medicine, and Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Department of Radiation Oncology, Department of Pharmacology, Department of Medicine, and Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

Channing J Der (CJ)

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Department of Radiation Oncology, Department of Pharmacology, Department of Medicine, and Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

Chad V Pecot (CV)

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Department of Radiation Oncology, Department of Pharmacology, Department of Medicine, and Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Department of Radiation Oncology, Department of Pharmacology, Department of Medicine, and Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

Classifications MeSH